SCHOTT Pharma AG & Co. KGaA Stock
Equities
1SXP
DE000A3ENQ51
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.04 EUR | -5.44% |
|
-10.88% | -32.27% |
| Dec. 05 | DAX Index Climbs as German Factory Orders Rise | MT |
| Dec. 05 | Global markets live: Netflix, Visa, Airbus, Ferrovial, Leonardo… |  |
| Capitalization | 2.56B 2.98B 2.4B 2.24B 4.13B 268B 4.49B 28.06B 10.83B 127B 11.18B 10.94B 463B | P/E ratio 2025 * |
17x | P/E ratio 2026 * | 15.1x |
|---|---|---|---|---|---|
| Enterprise value | 2.67B 3.1B 2.5B 2.33B 4.3B 279B 4.68B 29.21B 11.28B 132B 11.64B 11.39B 482B | EV / Sales 2025 * |
2.7x | EV / Sales 2026 * | 2.48x |
| Free-Float |
23% | Yield 2025 * |
0.94% | Yield 2026 * | 1.07% |
Last Transcript: SCHOTT Pharma AG & Co. KGaA
| 1 day | -5.44% | ||
| 1 week | -10.88% | ||
| Current month | -10.88% | ||
| 1 month | -6.48% | ||
| 3 months | -21.47% | ||
| 6 months | -39.47% | ||
| Current year | -32.27% |
| 1 week | 16.84 |  | 19.62 |
| 1 month | 16.84 | | 19.62 |
| Current year | 16.84 | | 30.25 |
| 1 year | 16.84 | | 30.25 |
| 3 years | 16.84 | | 43.4 |
| 5 years | 16.84 | | 43.4 |
| 10 years | 16.84 | | 43.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andreas Reisse
CEO | Chief Executive Officer | 64 | 2022-06-30 |
Reinhard Mayer
DFI | Director of Finance/CFO | 58 | 2025-07-31 |
Tobias Erfurth
IRC | Investor Relations Contact | - | 2024-08-29 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 2023-04-03 | |
Wolfgang Wienand
BRD | Director/Board Member | 53 | 2023-04-03 |
| Director/Board Member | 50 | 2023-04-03 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.44% | -10.88% | -35.45% | - | 2.98B | |
| -0.26% | -2.96% | +8.20% | +20.43% | 217B | |
| -0.62% | -3.77% | +20.65% | +31.50% | 130B | |
| +0.60% | -7.93% | +39.54% | +100.60% | 65.89B | |
| +0.10% | -0.03% | -11.84% | -20.64% | 55.36B | |
| +0.25% | +1.92% | +17.82% | +76.38% | 52.03B | |
| +0.87% | -1.13% | +21.95% | +43.42% | 25.84B | |
| +0.37% | +3.18% | -15.74% | -43.94% | 25.54B | |
| -0.33% | +2.89% | +18.63% | -34.55% | 24.14B | |
| -2.23% | -2.91% | -23.08% | +19.35% | 22.48B | |
| Average | -0.67% | -2.16% | +4.07% | +21.39% | 62.17B | |
| Weighted average by Cap. | -0.20% | -2.47% | +11.80% | +28.44% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 986M 1.15B 923M 861M 1.59B 103B 1.73B 10.8B 4.17B 48.75B 4.3B 4.21B 178B | 1.07B 1.25B 1B 936M 1.73B 112B 1.88B 11.75B 4.54B 53.01B 4.68B 4.58B 194B |
| Net income | 150M 174M 140M 131M 241M 15.68B 263M 1.64B 633M 7.4B 654M 640M 27.07B | 172M 200M 161M 150M 277M 18B 302M 1.88B 727M 8.5B 750M 734M 31.08B |
| Net Debt | 105M 123M 98.67M 91.97M 170M 11.03B 185M 1.15B 446M 5.21B 460M 450M 19.04B | 95M 111M 88.99M 82.95M 153M 9.95B 167M 1.04B 402M 4.7B 415M 406M 17.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 17.00 € | -8.01% | 394,809 |
| 25-12-04 | 18.48 € | +1.09% | 37,744 |
| 25-12-03 | 18.28 € | -2.25% | 52,049 |
| 25-12-02 | 18.70 € | -1.16% | 28,032 |
| 25-12-01 | 18.92 € | -1.05% | 43,659 |
Delayed Quote Xetra, December 05, 2025 at 12:20 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1SXP Stock
Select your edition
All financial news and data tailored to specific country editions
